000276330 001__ 276330
000276330 005__ 20240229154959.0
000276330 0247_ $$2doi$$a10.1186/s13014-023-02284-7
000276330 0247_ $$2pmid$$apmid:37248504
000276330 0247_ $$2altmetric$$aaltmetric:149109149
000276330 037__ $$aDKFZ-2023-01060
000276330 041__ $$aEnglish
000276330 082__ $$a610
000276330 1001_ $$aRegnery, Sebastian$$b0
000276330 245__ $$aComparison of different dose accumulation strategies to estimate organ doses after stereotactic magnetic resonance-guided adaptive radiotherapy.
000276330 260__ $$aLondon$$bBioMed Central$$c2023
000276330 3367_ $$2DRIVER$$aarticle
000276330 3367_ $$2DataCite$$aOutput Types/Journal article
000276330 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692022705_20940
000276330 3367_ $$2BibTeX$$aARTICLE
000276330 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276330 3367_ $$00$$2EndNote$$aJournal Article
000276330 500__ $$a#LA:E050#
000276330 520__ $$aRe-irradiation is frequently performed in the era of precision oncology, but previous doses to organs-at-risk (OAR) must be assessed to avoid cumulative overdoses. Stereotactic magnetic resonance-guided online adaptive radiotherapy (SMART) enables highly precise ablation of tumors close to OAR. However, OAR doses may change considerably during adaptive treatment, which complicates potential re-irradiation. We aimed to compare the baseline plan with different dose accumulation techniques to inform re-irradiation.We analyzed 18 patients who received SMART to lung or liver tumors inside prospective databases. Cumulative doses were calculated inside the planning target volumes (PTV) and OAR for the adapted plans and theoretical non-adapted plans via (1) cumulative dose volume histograms (DVH sum plan) and (2) deformable image registration (DIR)-based dose accumulation to planning images (DIR sum plan). We compared cumulative dose parameters between the baseline plan, DVH sum plan and DIR sum plan using equivalent doses in 2 Gy fractions (EQD2).Individual patients presented relevant increases of near-maximum doses inside the proximal bronchial tree, spinal cord, heart and gastrointestinal OAR when comparing adaptive treatment to the baseline plans. The spinal cord near-maximum doses were significantly increased in the liver patients (D2% median: baseline 6.1 Gy, DIR sum 8.1 Gy, DVH sum 8.4 Gy, p = 0.04; D0.1 cm³ median: baseline 6.1 Gy, DIR sum 8.1 Gy, DVH sum 8.5 Gy, p = 0.04). Three OAR overdoses occurred during adaptive treatment (DIR sum: 1, DVH sum: 2), and four more intense OAR overdoses would have occurred during non-adaptive treatment (DIR sum: 4, DVH sum: 3). Adaptive treatment maintained similar PTV coverages to the baseline plans, while non-adaptive treatment yielded significantly worse PTV coverages in the lung (D95% median: baseline 86.4 Gy, DIR sum 82.4 Gy, DVH sum 82.2 Gy, p = 0.006) and liver patients (D95% median: baseline 87.4 Gy, DIR sum 82.1 Gy, DVH sum 81.1 Gy, p = 0.04).OAR doses can increase during SMART, so that re-irradiation should be planned based on dose accumulations of the adapted plans instead of the baseline plan. Cumulative dose volume histograms represent a simple and conservative dose accumulation strategy.
000276330 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000276330 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276330 650_7 $$2Other$$aDeformable image Registration
000276330 650_7 $$2Other$$aDose accumulation
000276330 650_7 $$2Other$$aImage-guided Radiotherapy (IGRT)
000276330 650_7 $$2Other$$aLiver Cancer
000276330 650_7 $$2Other$$aMR-guided adaptive radiotherapy
000276330 650_7 $$2Other$$aPulmonary Cancer
000276330 650_7 $$2Other$$aStereotactic body Radiotherapy (SABR)
000276330 7001_ $$aLeiner, Lukas$$b1
000276330 7001_ $$aBuchele, Carolin$$b2
000276330 7001_ $$0P:(DE-He78)a8a8a2fe0df558db50514c1b568ca8ff$$aHoegen, Philipp$$b3$$udkfz
000276330 7001_ $$aSandrini, Elisabetta$$b4
000276330 7001_ $$aHeld, Thomas$$b5
000276330 7001_ $$aDeng, Maximilian$$b6
000276330 7001_ $$aEichkorn, Tanja$$b7
000276330 7001_ $$aRippke, Carolin$$b8
000276330 7001_ $$aRenkamp, C Katharina$$b9
000276330 7001_ $$aKönig, Laila$$b10
000276330 7001_ $$aLang, Kristin$$b11
000276330 7001_ $$aAdeberg, Sebastian$$b12
000276330 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b13$$udkfz
000276330 7001_ $$aKlüter, Sebastian$$b14
000276330 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b15$$eLast author$$udkfz
000276330 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/s13014-023-02284-7$$gVol. 18, no. 1, p. 92$$n1$$p92$$tRadiation oncology$$v18$$x1748-717X$$y2023
000276330 909CO $$ooai:inrepo02.dkfz.de:276330$$pVDB
000276330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a8a2fe0df558db50514c1b568ca8ff$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000276330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000276330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000276330 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000276330 9141_ $$y2023
000276330 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-30
000276330 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-30
000276330 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-30
000276330 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-30
000276330 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000276330 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000276330 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000276330 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:09:12Z
000276330 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:09:12Z
000276330 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:09:12Z
000276330 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000276330 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000276330 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000276330 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000276330 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000276330 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000276330 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000276330 980__ $$ajournal
000276330 980__ $$aVDB
000276330 980__ $$aI:(DE-He78)E050-20160331
000276330 980__ $$aUNRESTRICTED